Become A Wiser, More Profitable Investor

Leveraged Biotech ETFs: Hold LABU, Sell LABD (NYSEARCA:LABD) - Seeking Alpha

investing

The Biotechnology sector has been one of the first sectors to recover in June 2022, posting a healthy two-month rally. After the August top, SPDR® S&P Biotech ETF (XBI) entered a consolidation stage that finished with a big drop in February-March of 2023. For the last three weeks, XBI made small but consistent gains. My thesis is that this rally has good chances to establish a floor to the downward drift. On this basis, I rate XBI as a HOLD.

seekingalpha.com     Apr 19, 2023